Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Authors :: Roy S Herbst
Naiyer Rizvi
Karen Kelly
Vassiliki A Papadimitrakopoulou
Natasha B Leighl
Mary W Redman
Fred R Hirsch
Philip C Mack
Lawrence H Schwartz
James L Wade
William J Irvin
Sreekanth C Reddy
Jeffrey Crawford
Jeffrey D Bradley
Thomas E Stinchcombe
Suresh S Ramalingam
Jieling Miao
Katherine Minichiello
David R Gandara
Source :: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Publication Year :: 2021
Publisher :: BMJ Publishing Group, 2021.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools